| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 41.1M | 47.16M | 89.91M | 74.91M | 219.75M | 492.85M | 844.29M | 1.04B | 1.83B | 2.25B |
| Revenue Growth % | -0.19% | 0.15% | 0.91% | -0.17% | 1.93% | 1.24% | 0.71% | 0.23% | 0.76% | 0.23% |
| Cost of Goods Sold | 0 | 0 | 13.37M | 1.8M | 25.06M | 78.05M | 140.14M | 168.82M | 310.41M | 323.37M |
| COGS % of Revenue | - | - | 0.15% | 0.02% | 0.11% | 0.16% | 0.17% | 0.16% | 0.17% | 0.14% |
| Gross Profit | 41.1M | 47.16M | 76.55M | 73.11M | 194.69M | 414.8M | 704.14M | 868.6M | 1.52B | 1.92B |
| Gross Margin % | 1% | 1% | 0.85% | 0.98% | 0.89% | 0.84% | 0.83% | 0.84% | 0.83% | 0.86% |
| Gross Profit Growth % | -0.19% | 0.15% | 0.62% | -0.04% | 1.66% | 1.13% | 0.7% | 0.23% | 0.75% | 0.27% |
| Operating Expenses | 337.11M | 471.75M | 590M | 887.78M | 1.13B | 1.24B | 1.41B | 1.65B | 1.8B | 2.1B |
| OpEx % of Revenue | 8.2% | 10% | 6.56% | 11.85% | 5.16% | 2.52% | 1.67% | 1.59% | 0.98% | 0.93% |
| Selling, General & Admin | 60.61M | 89.35M | 199.37M | 382.36M | 479M | 588.42M | 620.64M | 770.66M | 795.65M | 975.53M |
| SG&A % of Revenue | 1.47% | 1.89% | 2.22% | 5.1% | 2.18% | 1.19% | 0.74% | 0.74% | 0.44% | 0.43% |
| Research & Development | 276.5M | 382.39M | 390.63M | 505.42M | 655.11M | 654.82M | 792.16M | 883.01M | 1B | 1.13B |
| R&D % of Revenue | 6.73% | 8.11% | 4.34% | 6.75% | 2.98% | 1.33% | 0.94% | 0.85% | 0.55% | 0.5% |
| Other Operating Expenses | 76K | 0 | -3.02M | 4.17M | 0 | 0 | -2.05M | 0 | 0 | 0 |
| Operating Income | -296.01M | -424.59M | -500.09M | -814.67M | -939.43M | -828.44M | -708.65M | -785.07M | -282.18M | -176.88M |
| Operating Margin % | -7.2% | -9% | -5.56% | -10.88% | -4.27% | -1.68% | -0.84% | -0.76% | -0.15% | -0.08% |
| Operating Income Growth % | 0.27% | -0.43% | -0.18% | -0.63% | -0.15% | 0.12% | 0.14% | -0.11% | 0.64% | 0.37% |
| EBITDA | -276.96M | -409.46M | -486.72M | -808.24M | -922.26M | -793.67M | -661.09M | -740.6M | -228.12M | -120.22M |
| EBITDA Margin % | -6.74% | -8.68% | -5.41% | -10.79% | -4.2% | -1.61% | -0.78% | -0.71% | -0.12% | -0.05% |
| EBITDA Growth % | 0.3% | -0.48% | -0.19% | -0.66% | -0.14% | 0.14% | 0.17% | -0.12% | 0.69% | 0.47% |
| D&A (Non-Cash Add-back) | 19.05M | 15.13M | 13.37M | 6.43M | 17.18M | 34.77M | 47.57M | 44.47M | 54.05M | 56.67M |
| EBIT | -296.01M | -424.59M | -500.09M | -760.67M | -885.25M | -771.1M | -709.12M | -971.02M | -312.3M | -235.52M |
| Net Interest Income | 5.86M | 8.31M | 12.24M | 29.26M | 33.45M | -72.69M | -141.44M | -131.16M | -25.66M | -19.87M |
| Interest Income | 5.86M | 8.31M | 12.24M | 29.26M | 33.45M | 11.81M | 1.58M | 24.81M | 95.56M | 121.99M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 84.5M | 143.02M | 155.97M | 121.22M | 141.86M |
| Other Income/Expense | 5.93M | 14.48M | 9.21M | 54M | 54.18M | -27.16M | -143.49M | -341.92M | -151.34M | -200.49M |
| Pretax Income | -290.07M | -410.11M | -490.87M | -760.67M | -885.25M | -855.6M | -852.14M | -1.13B | -433.52M | -377.38M |
| Pretax Margin % | -7.06% | -8.7% | -5.46% | -10.15% | -4.03% | -1.74% | -1.01% | -1.09% | -0.24% | -0.17% |
| Income Tax | 0 | 0 | 0 | 823K | 863K | 2.68M | 680K | 4.16M | 6.72M | -99.22M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1.02% | 0.74% |
| Net Income | -290.07M | -410.11M | -490.87M | -761.5M | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M | -278.16M |
| Net Margin % | -7.06% | -8.7% | -5.46% | -10.17% | -4.03% | -1.74% | -1.01% | -1.09% | -0.24% | -0.12% |
| Net Income Growth % | 0.2% | -0.41% | -0.2% | -0.55% | -0.16% | 0.03% | 0.01% | -0.33% | 0.61% | 0.37% |
| Net Income (Continuing) | -290.07M | -410.11M | -490.87M | -761.5M | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M | -278.16M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.45 | -4.79 | -5.42 | -7.57 | -8.11 | -7.46 | -7.20 | -9.30 | -3.52 | -2.18 |
| EPS Growth % | 0.29% | -0.39% | -0.13% | -0.4% | -0.07% | 0.08% | 0.03% | -0.29% | 0.62% | 0.38% |
| EPS (Basic) | -3.45 | -4.79 | -5.42 | -7.57 | -8.11 | -7.46 | -7.20 | -9.30 | -3.52 | -2.18 |
| Diluted Shares Outstanding | 83.99M | 85.6M | 90.55M | 100.59M | 109.26M | 114.99M | 118.45M | 121.69M | 124.91M | 127.65M |
| Basic Shares Outstanding | 83.99M | 85.6M | 90.55M | 100.59M | 109.26M | 114.99M | 118.45M | 121.69M | 124.91M | 127.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.11B | 671.88M | 1.76B | 1.2B | 1.72B | 2.61B | 2.81B | 2.69B | 2.98B | 3.3B |
| Cash & Short-Term Investments | 1.08B | 626.8M | 1.69B | 1.08B | 1.54B | 1.87B | 2.44B | 2.19B | 2.44B | 2.69B |
| Cash Only | 180.9M | 193.62M | 645.36M | 420.15M | 547.18M | 496.58M | 819.98M | 866.39M | 812.69M | 966.43M |
| Short-Term Investments | 899.64M | 433.18M | 1.05B | 664.01M | 988.98M | 1.38B | 1.62B | 1.33B | 1.63B | 1.73B |
| Accounts Receivable | 8.3M | 23.33M | 34M | 18.76M | 43.01M | 602.41M | 198.57M | 237.96M | 327.79M | 405.31M |
| Days Sales Outstanding | 73.7 | 180.6 | 138.03 | 91.41 | 71.44 | 446.14 | 85.85 | 83.72 | 65.44 | 65.8 |
| Inventory | 0 | 0 | 0 | 24.07M | 56.35M | 75.2M | 86.36M | 128.96M | 89.15M | 78.51M |
| Days Inventory Outstanding | - | - | - | 4.88K | 820.65 | 351.67 | 224.93 | 278.83 | 104.82 | 88.62 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 132.92M | 126.38M | 116.96M |
| Total Non-Current Assets | 281.12M | 590.93M | 229.99M | 374.11M | 679.27M | 792.28M | 834.73M | 854.11M | 847.18M | 944.7M |
| Property, Plant & Equipment | 27.81M | 114.57M | 181.9M | 320.66M | 646.38M | 706.51M | 733.63M | 738.63M | 725.79M | 693.93M |
| Fixed Asset Turnover | 1.48x | 0.41x | 0.49x | 0.23x | 0.34x | 0.70x | 1.15x | 1.40x | 2.52x | 3.24x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 251.84M | 324.8M | 13.92M | 44.83M | 14.82M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.47M | 151.56M | 34.17M | 8.62M | 18.07M | 85.77M | 101.09M | 115.48M | 111.29M | 133.9M |
| Total Assets | 1.39B | 1.26B | 1.99B | 1.57B | 2.4B | 3.41B | 3.64B | 3.55B | 3.83B | 4.24B |
| Asset Turnover | 0.03x | 0.04x | 0.05x | 0.05x | 0.09x | 0.14x | 0.23x | 0.29x | 0.48x | 0.53x |
| Asset Growth % | 0.28% | -0.09% | 0.58% | -0.21% | 0.52% | 0.42% | 0.07% | -0.03% | 0.08% | 0.11% |
| Total Current Liabilities | 62.1M | 131.7M | 144.25M | 179.49M | 352.59M | 585.27M | 695.71M | 767.91M | 967.79M | 1.19B |
| Accounts Payable | 16.79M | 54.47M | 28.36M | 59.71M | 49.88M | 51.97M | 73.43M | 98.09M | 55.52M | 88.42M |
| Days Payables Outstanding | - | - | 774.26 | 12.09K | 726.5 | 243.01 | 191.24 | 212.09 | 65.28 | 99.8 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 113.02M |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 12.32M | 15.27M | 35.81M | 40.87M | 68.3M | 110.75M | 130.66M | 170.98M | 177.16M | 214.4M |
| Current Ratio | 17.80x | 5.10x | 12.23x | 6.69x | 4.87x | 4.47x | 4.04x | 3.51x | 3.08x | 2.78x |
| Quick Ratio | 17.80x | 5.10x | 12.23x | 6.56x | 4.71x | 4.34x | 3.91x | 3.34x | 2.99x | 2.71x |
| Cash Conversion Cycle | - | - | - | -7.13K | 165.58 | 554.8 | 119.54 | 150.46 | 104.98 | 54.62 |
| Total Non-Current Liabilities | 59.7M | 210.89M | 84.05M | 93.34M | 603.85M | 1.81B | 2.36B | 2.94B | 3.08B | 2.99B |
| Long-Term Debt | 0 | 150M | 30M | 30M | 0 | 191.28M | 675.7M | 1.02B | 1.02B | 2.36B |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 276.13M | 293.04M | 281.35M | 261.34M | 243.1M | 229.54M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 6.73M | 11.5M | 10.97M | 62.88M | 9.33M | 1.1B | 1.25B | 1.46B | 1.63B | 398.11M |
| Total Liabilities | 121.8M | 342.59M | 228.3M | 272.84M | 956.44M | 2.39B | 3.06B | 3.7B | 4.05B | 4.17B |
| Total Debt | 0 | 150M | 30M | 30M | 303.82M | 521.19M | 997.59M | 1.32B | 1.31B | 2.74B |
| Net Debt | -1.28B | -43.62M | -615.36M | -390.15M | -243.35M | 24.61M | 177.62M | 453.85M | 492.7M | 1.78B |
| Debt / Equity | - | 0.16x | 0.02x | 0.02x | 0.21x | 0.51x | 1.70x | - | - | 40.89x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | -9.80x | -4.95x | -5.03x | -2.33x | -1.25x |
| Total Equity | 1.26B | 920.22M | 1.77B | 1.3B | 1.44B | 1.02B | 588.2M | -158.22M | -220.64M | 67.09M |
| Equity Growth % | 0.35% | -0.27% | 0.92% | -0.26% | 0.11% | -0.29% | -0.42% | -1.27% | -0.39% | 1.3% |
| Book Value per Share | 15.06 | 10.75 | 19.51 | 12.94 | 13.17 | 8.84 | 4.97 | -1.30 | -1.77 | 0.53 |
| Total Shareholders' Equity | 1.26B | 920.22M | 1.77B | 1.3B | 1.44B | 1.02B | 588.2M | -158.22M | -220.64M | 67.09M |
| Common Stock | 851K | 859K | 997K | 1.01M | 1.12M | 1.16M | 1.2M | 1.24M | 1.26M | 1.29M |
| Retained Earnings | -1.25B | -1.66B | -2.15B | -2.84B | -3.73B | -4.59B | -5.44B | -6.57B | -7.01B | -7.29B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.37M | -33.44M | -34.43M | -33.21M | -36.52M | -43.62M | -33.26M | -44.65M | -23.38M | -34.52M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -189.14M | -307.7M | -382.79M | -562.62M | -278.43M | -614.96M | -641.69M | -541.27M | 104.16M | -8.31M |
| Operating CF Margin % | -4.6% | -6.52% | -4.26% | -7.51% | -1.27% | -1.25% | -0.76% | -0.52% | 0.06% | -0% |
| Operating CF Growth % | -0.14% | -0.63% | -0.24% | -0.47% | 0.51% | -1.21% | -0.04% | 0.16% | 1.19% | -1.08% |
| Net Income | -290.07M | -410.11M | -490.87M | -761.5M | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M | -278.16M |
| Depreciation & Amortization | 19.05M | 15.13M | 13.37M | 6.43M | 54.37M | 74.44M | 89.69M | 85.55M | 97.03M | 56.67M |
| Stock-Based Compensation | 45.78M | 75.53M | 92.82M | 157.75M | 174.84M | 139.87M | 165.72M | 230.65M | 221.68M | 272.08M |
| Deferred Taxes | 0 | -6.98M | 1.89M | -3.56M | -11.29M | -54.04M | -55.7M | 0 | 0 | -106.76M |
| Other Non-Cash Items | 984K | 1.51M | 2.91M | -6.84M | -12.61M | 95.75M | 174.24M | 309.24M | 214.93M | 261.94M |
| Working Capital Changes | 35.12M | 17.22M | -2.9M | 45.1M | 402.38M | -12.7M | -162.82M | -35.55M | 10.76M | -214.08M |
| Change in Receivables | 31.64M | -15.04M | -10.67M | 15.24M | -24.24M | -56.24M | -101.8M | -45.6M | -87.94M | -86.55M |
| Change in Inventory | 0 | 0 | 0 | -22.64M | -32.41M | -35.43M | -26.41M | -34.14M | 18.37M | 13.59M |
| Change in Payables | 1.68M | 10.1M | -4.94M | 15.48M | 36.61M | 117.38M | 88.24M | 191.77M | 80.84M | 91.09M |
| Cash from Investing | -321.32M | 142.59M | -290.36M | 272.94M | -417.68M | -435.52M | -273.3M | 169.35M | -336.35M | -116.84M |
| Capital Expenditures | -12.95M | -64.56M | -104.21M | -126.89M | -140.16M | -70.36M | -76.37M | -72.06M | -62.21M | -34.28M |
| CapEx % of Revenue | 0.32% | 1.37% | 1.16% | 1.69% | 0.64% | 0.14% | 0.09% | 0.07% | 0.03% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.47M | -150M | 120M | -14.82M | 23M | -31.2M | -4.36M | -13.19M | -4.44M | 57.76M |
| Cash from Financing | 616.18M | 177.83M | 1.12B | 65.47M | 823.18M | 994.98M | 1.25B | 425.75M | 172.13M | 294.16M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 31.14M | 14.13M | 83.89M | 0 | 71.28M | 695.48M | 500.85M | -87.61M | 24.67M | -8.79M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -202.09M | -372.26M | -487M | -689.5M | -418.58M | -685.32M | -718.07M | -613.33M | 41.95M | -42.59M |
| FCF Margin % | -4.92% | -7.89% | -5.42% | -9.2% | -1.9% | -1.39% | -0.85% | -0.59% | 0.02% | -0.02% |
| FCF Growth % | -0.16% | -0.84% | -0.31% | -0.42% | 0.39% | -0.64% | -0.05% | 0.15% | 1.07% | -2.02% |
| FCF per Share | -2.41 | -4.35 | -5.38 | -6.85 | -3.83 | -5.96 | -6.06 | -5.04 | 0.34 | -0.33 |
| FCF Conversion (FCF/Net Income) | 0.65x | 0.75x | 0.78x | 0.74x | 0.31x | 0.72x | 0.75x | 0.48x | -0.24x | 0.03x |
| Interest Paid | 0 | 1.1M | 2.43M | 775K | 172K | 0 | 0 | 0 | 0 | 67.58M |
| Taxes Paid | 66K | 111K | 114K | 1.07M | 2.57M | 0 | 0 | 0 | 0 | 14.36M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -26.36% | -37.54% | -36.54% | -49.63% | -64.66% | -69.92% | -106.31% | -526.14% | - | -414.62% |
| Return on Invested Capital (ROIC) | -22.83% | -32.49% | -36.99% | -59.24% | -66.87% | -55.57% | -58.84% | -110.94% | -74.56% | -12.54% |
| Gross Margin | 100% | 100% | 85.13% | 97.59% | 88.6% | 84.16% | 83.4% | 83.73% | 83.02% | 85.62% |
| Net Margin | -705.83% | -869.63% | -545.95% | -1016.58% | -403.24% | -174.15% | -101.01% | -109.04% | -24.08% | -12.37% |
| Debt / Equity | - | 0.16x | 0.02x | 0.02x | 0.21x | 0.51x | 1.70x | - | - | 40.89x |
| Interest Coverage | - | - | - | - | - | -9.80x | -4.95x | -5.03x | -2.33x | -1.25x |
| FCF Conversion | 0.65x | 0.75x | 0.78x | 0.74x | 0.31x | 0.72x | 0.75x | 0.48x | -0.24x | 0.03x |
| Revenue Growth | -18.72% | 14.75% | 90.66% | -16.69% | 193.36% | 124.28% | 71.31% | 22.88% | 76.23% | 22.97% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Product | 12.54M | 166.54M | 361.52M | 662.14M | 894.33M | 1.24B | 1.65B |
| Product Growth | - | 1228.58% | 117.08% | 83.15% | 35.07% | 38.82% | 32.60% |
| GIVLAARI | - | - | - | - | - | 219.25M | 255.87M |
| GIVLAARI Growth | - | - | - | - | - | - | 16.70% |
| Royalty | - | - | - | 1.2M | 8.18M | - | - |
| Royalty Growth | - | - | - | - | 583.70% | - | - |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| UNITED STATES | - | 116.45M | 151.57M | 18.88M | 27.7M | 411.17M | 630.61M |
| UNITED STATES Growth | - | - | 30.16% | -87.55% | 46.74% | 1384.47% | 53.37% |
| Europe | - | - | 333K | 38.95M | 37.91M | 210.92M | 235.44M |
| Europe Growth | - | - | - | 11596.40% | -2.65% | 456.29% | 11.63% |
| Non-US Or Europe | - | 50.09M | 46.75M | 1.76M | 4.17M | 75.77M | 104.4M |
| Non-US Or Europe Growth | - | - | -6.65% | -96.23% | 136.74% | 1717.49% | 37.78% |
Alnylam Pharmaceuticals, Inc. (ALNY) reported $3.21B in revenue for fiscal year 2024. This represents a 3779% increase from $82.8M in 2011.
Alnylam Pharmaceuticals, Inc. (ALNY) grew revenue by 23.0% over the past year. This is strong growth.
Yes, Alnylam Pharmaceuticals, Inc. (ALNY) is profitable, generating $43.6M in net income for fiscal year 2024 (-12.4% net margin).
Alnylam Pharmaceuticals, Inc. (ALNY) has a return on equity (ROE) of -414.6%. Negative ROE indicates the company is unprofitable.
Alnylam Pharmaceuticals, Inc. (ALNY) generated $221.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.